Blog
Technology, end-of-life care, and 'Being Mortal'
Atul Gawande's recent book on end-of-life care is inspiring and thought-provoking - and an important must-read for tech experts, entrepreneurs, and investors.
Biotech's R&D Talent Opportunity
Mid-level "leader-doers" make the magic happen in R&D. Here's how to get them.
Pharma's hunt for academic innovation
Pharma overlooks many potentially valuable collaborations by focusing exclusively on the academic "A-list".
Enabling R&D collaborations between academia and pharma
Many academic researchers aren't aware of opportunities to collaborate with pharma R&D organizations - so we created a directory to help them. Check it out!
The case for "biotech paranoia"
Biotechs need to get anxious - really anxious - about how changes in the industry will affect Pharma deal-making.
Drug pricing is the new Big Pharma giant-killer
Is the new contracting deal in hepatitis C a meaningless blip, or the “end of days” for biopharma? (Spoiler alert: "no” and “no”.)
You can't have value-based drug pricing without value
Think you can charge a lot more than generics when your drug is only a little bit better? Think again.
Making clinical development more investable with “financially adaptive trials”
Clinical trials are a terrible investment. But fear not – in our NRDD article, we show a path forward.
Where's the commercial innovation in pharma?
Pharma commercial teams are doing business like it's 2004 ... or maybe even 1994. It's time for a reboot.
Should pharma R&D and commercial "just be friends"?
GlaxoSmithKline is giving up its commercial presence in oncology, but keeping cancer R&D. This could be a huge deal, and a harbinger of things to come.